Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis
Brain · 05.03.2026 · 149 (3) · 951-962
DOI: 10.1093/brain/awaf286 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Brain, online erschienen am 04.08.2025. Verfasst von Tomas Kalincik und 48 weiteren Autor:innen. Beteiligte Einrichtung: Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne 3000, Australia. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Multiple Sclerosis, Relapsing-Remitting, Alemtuzumab, Cladribine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Health and Medical Research Council of Australia, Multiple Sclerosis Australia, MS Foundation of Canada.
Abstract (Originalsprache)
In the treatment of relapsing-remitting multiple sclerosis, autologous haematopoietic stem cell transplant (AHSCT) and immune-reconstitution therapies show several similarities. These treatment strategies have not yet been compared head-to-head. This study emulated pairwise trials of comparative effectiveness of stem cell transplant versus immune-reconstitution therapies cladribine and alemtuzumab. This cohort/registry study of comparative treatment effectiveness included data from seven specialist multiple sclerosis centres with AHSCT programmes (RESCUE-MS) and international MSBase registry during 2006–2023. The study included patients with relapsing-remitting multiple sclerosis treated with AHSCT, cladribine or alemtuzumab, with a minimum of 2-months follow-up before commencing study therapy and ≥2 disability assessments after commencing the study therapy. Patients were matched on a propensity score derived from their clinical and demographic characteristics. The matched groups were compared according to annualized relapse rates, freedom from relapses and 6-month confirmed disability worsening and improvement (measured with the Expanded Disability Status Scale). The matching of 143 (stem cell) to 283 cladribine-treated patients and 134 (stem cell) to 562 alemtuzumab-treated patients reduced the measured differences between the groups by 98% and 96%, respectively. The matched patients had high mean disease activity (>0.8 relapses in the prior 2 years), mean Expanded Disability Status Scale scores of 3–4, and were followed-up for a mean of 3.8–3.9 (stem cell), 1.9 (cladribine) or 4.5 years (alemtuzumab). Compared with cladribine, stem cell transplant was associated with a lower risk of relapse [mean annualized relapse rate ± standard deviation (SD): 0.05 ± 0.28 versus 0.16 ± 0.39, respectively; hazard ratio: 0.24; 95% confidence interval (CI): 0.15–0.41], similar risk of disability worsening (hazard ratio: 0.70; 95% CI: 0.34–1.43) and higher probability of disability improvement (hazard ratio: 2.19; 95% CI: 1.31–3.66). Compared with alemtuzumab, stem cell transplant was associated with a lower risk of relapses (mean annualized relapse rate ± SD: 0.04 ± 0.23 versus 0.09 ± 0.21, respectively; hazard ratio: 0.52; 95% CI: 0.29–0.93), similar risk of disability worsening (hazard ratio: 0.95; 95% CI: 0.53–1.72) and higher probability of disability improvement (hazard ratio: 2.03; 95% CI: 1.23–3.34). Thirty-four per cent of patients treated with stem cell transplant experienced delayed complications, mainly infections. No treatment-associated deaths were reported. Among patients with active relapsing-remitting multiple sclerosis and moderate disability, AHSCT is superior to cladribine and alemtuzumab at suppressing relapses and enabling recovery of neurological function. The high effectiveness of stem cell transplant is likely attributable to a complex interplay between immune suppression and reconstitution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne 3000, Australia.
- CORe, Department of Medicine, University of Melbourne, Melbourne 3000, Australia.
- Department of Medicine, University of Ottawa, Ottawa, Canada K1N 6N5.
- Ottawa Hospital Research Institute, Ottawa, Canada K1H 8L6.
- Department of Neurology, St Vincent's Hospital Sydney, Sydney 2010, Australia.
- St Vincent's Clinical School, University of New South Wales, Sydney 2010, Australia.
ORCID-Profile: Tomas Kalincik, Izanne Roos, Joachim Burman, Alasdair Coles, Michael Barnett, Simón Cárdenas-Robledo
Förderung
- National Health and Medical Research Council of Australia
- Multiple Sclerosis Australia
- MS Foundation of Canada
Zitieren
APA
Kalincik, T., Sharmin, S., Roos, I., Freedman, M. S., Atkins, H., Massey, J., Sutton, I., Withers, B., Burman, J., Torkildsen, Ø., Bø, L., Lehmann, A. K., Havrdova, E. K., Krasulova, E., Trneny, M., Kozak, T., Macdonell, R., Brown, J. W. L., Coles, A., …, & Snowden, J. A. (2026). Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis. Brain, 149(3), 951-962. https://doi.org/10.1093/brain/awaf286
Vancouver
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Massey J, et al. Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis. Brain. 2026;149(3):951-962. doi:10.1093/brain/awaf286
BibTeX
@article{Kalincik2026,
author = {Kalincik, Tomas and Sharmin, Sifat and Roos, Izanne and Freedman, Mark S and Atkins, Harold and Massey, Jennifer and Sutton, Ian and Withers, Barbara and Burman, Joachim and Torkildsen, Øivind and Bø, Lars and Lehmann, Anne Kristine and Havrdova, Eva Kubala and Krasulova, Eva and Trneny, Marek and Kozak, Tomas and Macdonell, Richard and Brown, J William L and Coles, Alasdair and van der Walt, Anneke and Butzkueven, Helmut and Van Wijmeersch, Bart and Lechner-Scott, Jeannette and Barnett, Michael and Laureys, Guy and Willekens, Barbara and Buzzard, Katherine and Skibina, Olga and Di Gregorio, Maria and Hodgkinson, Suzanne and Ozakbas, Serkan and Meca-Lallana, Jose E and Alroughani, Raed and Prevost, Julie and Foschi, Matteo and Surcinelli, Andrea and Neri, Stefano and Eichau, Sara and McCombe, Pamela and John, Nevin and Cárdenas-Robledo, Simón and Oh, Jiwon and Sanchez-Menoyo, Jose Luis and Patti, Francesco and Gerlach, Oliver and Blanco, Yolanda and Grammond, Pierre and Sharrack, Basil and Snowden, John A},
title = {Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis},
journal = {Brain},
year = {2026},
volume = {149},
number = {3},
pages = {951--962},
doi = {10.1093/brain/awaf286}
}
EUVIMED